Chen J, Radford M J, Wang Y, Krumholz H M
Yale University School of Medicine (JC), Yale University School of Medicine, New Haven, Connecticut, USA.
Am J Med. 2000 Apr 15;108(6):460-9. doi: 10.1016/s0002-9343(00)00331-4.
Whether patients with acute myocardial infarction who are treated by cardiologists have better outcomes than patients treated by generalist physicians is controversial. Because some of the survival benefit associated with cardiology care may be due to baseline differences in patient characteristics, we evaluated how differences in case-mix of comorbid illness and functional limitations may explain the association between specialty care and survival.
We examined the records of 109,243 Medicare beneficiaries hospitalized for myocardial infarction from 1994 to 1995 from the national Cooperative Cardiovascular Project to evaluate the association of physician specialty with 30-day and 1-year mortality. We assessed the extent to which this relation was mediated by differences in the use of guideline-supported therapies (aspirin, beta-blockers, reperfusion, angiotensin-converting enzyme inhibitors) or differences in the clinical characteristics of the patients.
Patients who had board-certified cardiologists as attending physicians had the least number of comorbid conditions, whereas patients who had general practitioners or internal medicine subspecialists as attending physicians usually had the most comorbidities. Cardiologists had the greatest use of most guideline-supported therapies, and general practitioners had the lowest use. After adjustment for severity of myocardial infarction, clinical presentation, and hospital characteristics, patients treated by cardiologists were less likely to die within 1 year (relative risk [RR] = 0.92, 95%, confidence interval [CI]: 0.89 to 0. 95), and patients cared for by other general practitioners were more likely to die within 1 year (RR = 1.09, 95% CI: 1.03 to 1.14), than patients cared for by general internists. After adjusting for additional measures of comorbid illness and functional limitations, the 1-year survival benefit associated with cardiology care was attenuated relative to internists (RR = 0.97, 95% CI: 0.94 to 1.0), and the excess mortality associated with general practitioners decreased (RR = 1.05, 95% CI: 1.00 to 1.11). After further adjustment for the use of guideline-supported therapies, both differences in 1-year survival between patients treated by cardiologists or general practitioners were not significantly different from those of patients treated by internists.
Studies comparing outcomes by physician specialties that do not adjust adequately for differences in patient characteristics may attribute more benefit than is appropriate to specialists who treat patients who have fewer comorbid conditions. Some of the remaining benefit-at least among patients with myocardial infarction-may be attributable to greater use of recommended therapies.
由心脏病专家治疗的急性心肌梗死患者是否比由普通内科医生治疗的患者有更好的预后存在争议。由于与心脏病治疗相关的一些生存获益可能归因于患者特征的基线差异,我们评估了合并症和功能受限的病例组合差异如何解释专科治疗与生存之间的关联。
我们检查了1994年至1995年全国心血管合作项目中109,243名因心肌梗死住院的医疗保险受益人的记录,以评估医生专业与30天和1年死亡率之间的关联。我们评估了这种关系在多大程度上是由指南支持疗法(阿司匹林、β受体阻滞剂、再灌注、血管紧张素转换酶抑制剂)使用的差异或患者临床特征的差异所介导的。
以获得委员会认证的心脏病专家为主治医生的患者合并症数量最少,而以全科医生或内科亚专科医生为主治医生的患者通常合并症最多。心脏病专家对大多数指南支持疗法的使用最多,而全科医生的使用最少。在调整了心肌梗死的严重程度、临床表现和医院特征后,与内科医生治疗的患者相比,由心脏病专家治疗的患者在1年内死亡的可能性较小(相对风险[RR]=0.92,95%置信区间[CI]:0.89至0.95),而由其他全科医生治疗的患者在1年内死亡的可能性较大(RR=1.09,95%CI:1.03至1.14)。在调整了合并症和功能受限的其他测量指标后,与内科医生相比,与心脏病治疗相关的1年生存获益有所减弱(RR=0.97,95%CI:0.94至1.0),与全科医生相关的额外死亡率有所下降(RR=1.05,95%CI:1.00至1.11)。在进一步调整指南支持疗法的使用后,心脏病专家或全科医生治疗的患者之间1年生存率的差异与内科医生治疗的患者之间的差异均无显著差异。
在未充分调整患者特征差异的情况下比较医生专业的预后研究,可能会将比实际更合适的更多益处归因于治疗合并症较少患者的专科医生。至少在心肌梗死患者中,剩余的一些益处可能归因于对推荐疗法的更多使用。